EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read moreMon, 07th Jun 2021 10:11
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read moreWednesday 24 April | |
1Spatial PLC | Full Year Results |
abrdn PLC | Trading Statement |
Ecora Resources PLC | Trading Statement |
Fresnillo PLC | Trading Statement |
Lloyds Banking Group PLC | Q1 Results |
Nichols PLC | Trading Statement |
PensionBee Group PLC | First Quarter Results |
PZ Cussons PLC | Trading Statement |
Quilter PLC | Q1 Results |
Reckitt Benckiser Group PLC | Trading Statement |
Sanderson Design Group PLC | Full Year Results |
Serica Energy PLC | Full Year Results |
Star Energy Group PLC | Full Year Results |
Tortilla Mexican Grill PLC | Full Year Results |
Tracsis PLC | Half Year Results |
Warpaint London PLC | Full Year Results |
Thursday 25 April | |
Aquila European Renewables PLC | Full Year Results |
Argo Blockchain PLC | Full Year Results |
AstraZeneca PLC | Q1 Results |
Barclays PLC | Q1 Results |
Checkit PLC | Full Year Results |
Coca-Cola Europacific Partners PLC | Trading Statement |
Destiny Pharma PLC | Full Year Results |
Dillistone Group PLC | Full Year Results |
Focusrite PLC | Half Year Results |
Gem Diamonds Ltd | Trading Statement |
Hikma Pharmaceuticals PLC | Trading Statement |
Hummingbird Resources PLC | Trading Statement |
Ibstock PLC | Trading Statement |
Inchcape PLC | Trading Statement |
J Sainsbury PLC | Full Year Results |
London Stock Exchange Group PLC | Q1 Results |
Persimmon PLC | Trading Statement |
Pinewood Technologies Group PLC | Full Year Results |
PPHE Hotel Group Ltd | Trading Statement |
PureTech Health PLC | Full Year Results |
Relx PLC | Trading Statement |
Renewi PLC | Trading Statement |
Schroders PLC | Q1 Results |
Skillcast Group PLC | Full Year Results |
Travis Perkins PLC | Trading Statement |
Trifast PLC | Trading Statement |
Unilever PLC | Q1 Results |
WAG Payment Solutions PLC | Trading Statement |
Weir Group PLC | Trading Statement |
WH Smith PLC | Half Year Results |
WPP PLC | Trading Statement |
Zinc Media Group PLC | Full Year Results |
Friday 26 April | |
Facilities by ADF PLC | Full Year Results |
Kingspan Group PLC | Trading Statement |
NatWest Group PLC | Q1 Results |
Pearson PLC | Trading Statement |
Record PLC | Trading Statement |
Smurfit Kappa Group PLC | Trading Statement |
Taylor Maritime Investments Ltd | Trading Statement |
Monday 29 April | |
Beazley PLC | Trading Statement |
Biome Technologies PLC | Full Year Results |
Christie Group PLC | Full Year Results |
Gresham Technologies PLC | Full Year Results |
Jadestone Energy PLC | Full Year Results |
Oxford BioMedica PLC | Full Year Results |
SpaceandPeople PLC | Full Year Results |
Tuesday 30 April | |
Avacta Group PLC | Full Year Results |
Card Factory PLC | Full Year Results |
Capital & Regional PLC | Full Year Results |
Coca-Cola HBC AG | Trading Statement |
Elementis PLC | Trading Statement |
essensys PLC | Half Year Results |
Fadel Partners Inc | Full Year Results |
Glencore PLC | Trading Statement |
Hargreaves Lansdown PLC | Trading Statement |
Howden Joinery PLC | Trading Statement |
HSBC Holdings PLC | Q1 Results |
Kelso Group PLC | Full Year Results |
Northcoders Group PLC | Full Year Results |
Phoenix Spree Deutschland Ltd | Full Year Results |
RBG Holdings PLC | Full Year Results |
Rotork PLC | Trading Statement |
Safestore Holdings PLC | Half Year Results |
Shield Therapeutics PLC | Full Year Results |
St James's Place PLC | Trading Statement |
Whitbread PLC | Full Year Results |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
Read more(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.
Read moreAvacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.
Read more(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.
Read moreAvacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.
Read more(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.
Read moreAvacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.
Read more